Moderna Inc (NASDAQ) (NYSE:MRNA) has been given an average broker rating score of 1.19 (Strong Buy) from the eight analysts that provide coverage for the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a buy rating and six have issued a strong buy rating on the company. Moderna Inc (NASDAQ)’s rating score has improved by 1.7% from 90 days ago as a result of various analysts’ ratings changes.
Brokerages have set a 1-year consensus price objective of $27.38 for the company and are forecasting that the company will post ($0.35) EPS for the current quarter, according to Zacks. Zacks has also assigned Moderna Inc (NASDAQ) an industry rank of 54 out of 255 based on the ratings given to related companies.
Separately, Chardan Capital reiterated a “buy” rating on shares of Moderna Inc (NASDAQ) in a research report on Sunday, April 7th.
About Moderna Inc (NASDAQ)
Moderna, Inc, a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Moderna Inc (NASDAQ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna Inc (NASDAQ) and related companies with MarketBeat.com's FREE daily email newsletter.